New Delhi, March 11 -- Lupin Ltd's recent launch of generic version of Xarelto 2.5 mg is one of the several it has planned for the US market. The estimated annual sales of the product, used as an anticoagulant agent, is about $450 million in the US. To that extent, this launch adds to Lupin's FY26 revenues.

The company derived nearly one-third of its revenue from the US market in the nine months ended December (9MFY25). Additionally, Lupin has a strong pipeline of more than 20 respiratory products and 40 injectable products in the development stage to leverage its market presence.

It plans to file over 30 abbreviated new drug applications (ANDAs) in the next two years. Of this, more than 50% will be complex generic products-a growing ca...